Clinical Trial Detail

NCT ID NCT02605356
Title Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bayer
Indications

multiple myeloma

Therapies

Radium Ra 223 dichloride

Bortezomib

Dexamethasone

Age Groups: adult

No variant requirements are available.